New Advances in Targeted Therapy of HER2-Negative Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 21

PMID 35311116

Authors

Junsha An

Cheng Peng

Xiaofang Xie

Fu Peng

Affiliations

Soon will be listed here.

Abstract

Breast cancer has an extremely high incidence in women, and its morbidity and mortality rank first among female tumors. With the increasing development of molecular biology and genomics, molecular targeted therapy has become one of the most active areas in breast cancer treatment research and has also achieved remarkable achievements. However, molecular targeted therapy is mainly aimed at HER2-positive breast cancer and has not yet achieved satisfactory curative effect on HER2-negative breast cancer. This article describes the potential targets that may be used for breast cancer treatment from the aspects of PI3K/AKT signaling pathway, DDR, angiogenesis, the cell cycle, breast cancer stem cells, , and explores possible inhibitors for the treatment of HER2-negative breast cancer, such as PI3K inhibitors, AKT inhibitors and m-TOR inhibitors that inhibit the PI3K/AKT signaling pathway, small molecule tyrosine kinase inhibitors that restrain angiogenesis, CDK inhibitors, aurora kinase inhibitors and HDAC inhibitors that block cell cycle, as well as the drugs targeting breast cancer stem cells which have been a hit, aiming to provide a new idea and strategy for the treatment of HER2-negative breast cancer.

Citing Articles

Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy.

An J, Lu Y, Chen Y, Chen Y, Zhou Z, Chen J Front Immunol. 2025; 15:1499301.

PMID: 39749323 PMC: 11693744. DOI: 10.3389/fimmu.2024.1499301.

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer.

Cardoso F, Hirshfield K, Kraynyak K, Tryfonidis K, Bardia A NPJ Breast Cancer. 2024; 10(1):104.

PMID: 39643613 PMC: 11624285. DOI: 10.1038/s41523-024-00704-9.

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Hagelstein I, Wessling L, Rochwarger A, Zekri L, Klimovich B, Tegeler C J Transl Med. 2024; 22(1):902.

PMID: 39367484 PMC: 11452943. DOI: 10.1186/s12967-024-05689-4.

Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: cell-based anticancer studies.

Maji A, Himaja A, Nikhitha S, Rana S, Paul A, Samanta A RSC Med Chem. 2024; 15(9):3057-3069.

PMID: 39309361 PMC: 11411633. DOI: 10.1039/d4md00279b.

Oxygen tension-dependent variability in the cancer cell kinome impacts signaling pathways and response to targeted therapies.

Adebayo A, Bhat-Nakshatri P, Davis C, Angus S, Erdogan C, Gao H iScience. 2024; 27(6):110068.

PMID: 38872973 PMC: 11170190. DOI: 10.1016/j.isci.2024.110068.

References

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z . Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014; 135(8):1961-9. DOI: 10.1002/ijc.28829. View

Han F, Lin S, Liu P, Liu X, Tao J, Deng X . Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. ACS Med Chem Lett. 2015; 6(4):434-8. PMC: 4394348. DOI: 10.1021/ml5005014. View

Wimmer K, Bolliger M, Bago-Horvath Z, Steger G, Kauer-Dorner D, Helfgott R . Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival. Ann Surg Oncol. 2019; 27(5):1700-1707. PMC: 7138765. DOI: 10.1245/s10434-019-08089-x. View

Chung A, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D . Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012; 227(4):404-16. DOI: 10.1002/path.4052. View

Yan J, Qiu P, Zhang X, Zhang Y, Mi L, Peng C . Biochanin A from Chinese Medicine: An Isoflavone with Diverse Pharmacological Properties. Am J Chin Med. 2021; 49(7):1623-1643. DOI: 10.1142/S0192415X21500750. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G . A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013; 5(3):353-65. PMC: 3598077. DOI: 10.1002/emmm.201201760. View

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B . Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021; 2(3):315-340. PMC: 8554658. DOI: 10.1002/mco2.55. View

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5(10):835-44. DOI: 10.1038/nrd2130. View

10.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

11.

Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P . Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther. 2019; 27(7):1252-1261. PMC: 6612664. DOI: 10.1016/j.ymthe.2019.04.018. View

12.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

13.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

14.

Peyressatre M, Prevel C, Pellerano M, Morris M . Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 2015; 7(1):179-237. PMC: 4381256. DOI: 10.3390/cancers7010179. View

15.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

16.

Peng F, Tang H, Du J, Chen J, Peng C . Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/[Formula: see text]-Catenin. Am J Chin Med. 2021; 49(2):505-523. DOI: 10.1142/S0192415X21500233. View

17.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

18.

Hanahan D . Signaling vascular morphogenesis and maintenance. Science. 1997; 277(5322):48-50. DOI: 10.1126/science.277.5322.48. View

19.

Li J, Yang Y, Liu Q, Pan S, He Z, Zhang X . The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther. 2015; 9:1627-52. PMC: 4365748. DOI: 10.2147/DDDT.S75378. View

20.

Zardavas D, Tryfonidis K, Goulioti T, Piccart M . Targeted adjuvant therapy in breast cancer. Expert Rev Anticancer Ther. 2016; 16(12):1263-1275. DOI: 10.1080/14737140.2016.1247698. View